Biomimetic Nanomaterials Triggered Ferroptosis for Cancer Theranostics

10.3389/fchem.2021.768248Frontiers in Chemistry976824

Disturbing cytoskeleton by engineered nanomaterials for enhanced cancer therapeutics

Cytoskeleton plays a significant role in the shape change, migration, movement, adhesion, cytokinesis, and phagocytosis of tumor cells. In clinical practice, some anti-cancer drugs achieve cytoskeletal therapeutic effects by acting on different cytoskeletal protein components. However, in the absence of cell-specific targeting, unnecessary cytoskeletal recombination in organisms would be disastrous, which would also bring about severe side effects during anticancer process. Nanomedicine have been proven to be superior to some small molecule drugs in cancer treatment due to better stability and targeting, and lower side effects. Therefore, this review summarized the recent developments of various nanomaterials disturbing cytoskeleton for enhanced cancer therapeutics, including carbon, noble metals, metal oxides, black phosphorus, calcium, silicon, polymers, peptides, and metal-organic frameworks, etc. A comprehensive analysis of the characteristics of cytoskeleton therapy as well as the future prospects and challenges towards clinical application were also discussed. We aim to drive on this emerging topic through refreshing perspectives based on our own work and what we have also learnt from others. This review will help researchers quickly understand relevant cytoskeletal therapeutic information to further advance the development of cancer nanomedicine

Improving the Corrosion Resistance of AZ91 Magnesium Alloy by Surface Coating TiO₂ Layers

This study adopts the sol-gel method to prepare a TiO2 coating on the surface of the AZ91 magnesium alloy, hydrolyse C16H36O4Ti to generate the TiO2 coating and form a film with excellent corrosion resistance on the surface of an AZ91 magnesium alloy. The composition, surface structure and microstructure of the TiO2 coatings are characterised via X-ray diffraction (XRD) and scanning electron microscopy. The corrosion performance of the surface coatings was investigated through hydrogen evolution experiments and electrochemical tests. The results demonstrate that TiO2 sols prepared from a mixture of hydrochloric acid, deionised water, C16H36O4Ti and anhydrous ethanol can form stable layers on the surface of an AZ91 magnesium alloy after heat treatment. The results of hydrogen evolution experiments and electrochemical tests reveal that the TiO2 coating can effectively improve the corrosion resistance of the AZ91 magnesium alloy

Analysis of prevalence of adverse events connected with anti-tuberculosis drugs during pregnancy: A meta-analysis

Background: Mycobacterium tuberculosis infection is transmitted among humans via airborne droplets. The drugs used in the initial treatment regimen for tuberculosis (TB) cross the placenta, raising some concerns regarding their safety during pregnancy may provide a more valid approach for evaluating the relative influence of various risk factors. Adverse events of anti-tuberculous (anti-TB) drug during pregnancy remain uncertain and controversial issues. Methods: We performed a systematic analysis to study the adverse events connected with anti-TB drugs usage during pregnancy. The risk of bias in the included studies was assessed using the Cochrane Collaboration criteria. Interstudy heterogeneity was assessed via Cochran's test. Assuming heterogeneity, a random-effects model was applied. Outcomes were pooled using the inverse variance method. Besides, a funnel plot was created to assess publication bias. We used Egger's linear regression test of funnel plot asymmetry, modified to accommodate inter-study heterogeneity. Effect estimates and confidence intervals for all studies were depicted on a forest plot. Results: The prevalence of total adverse events for all anti-TB drugs was 25.9 %. According to the drug category, the prevalence of total adverse events was 50 % for ethambutol, 32.6 % for the six-month directly observed treatment short-course (DOTS), 31.4 % for the nine-month DOTS, and 13.7 % for isoniazid. Conclusions: There is a high rate of reported adverse events associated with anti-TB drugs usage during pregnancy. We concluded that more high-quality clinical studies and research works are needed to reach a conclusive decision on the safety of the treatment of TB among pregnant women